Impiricus runs an AI-powered HCP Engagement Engine that delivers evidence-based pharmaceutical content to opted-in healthcare providers through real-time channels.
Impiricus operates an AI-powered HCP Engagement Engine, a platform that connects healthcare professionals with pharmaceutical resources by delivering evidence-based content directly to opted-in providers through real-time channels. The system uses artificial intelligence to target and route material, with the stated aim of reducing the noise between physicians and pharmaceutical information. Its scale is measurable: 95% of messages are opened within three minutes, and the platform reaches roughly 30% of physicians who do not engage through traditional channels.
The company claims the largest opted-in network of healthcare providers of its kind, working across the pharmaceutical, healthcare and life-sciences sectors in North America. Impiricus reports that it helped 1 million patients access therapy in 2025, and it ranked first on Deloitte's 2025 Technology Fast 500 as the fastest-growing company in North America. Technical work spans artificial intelligence, real-time messaging and communication channels, healthcare provider engagement platforms, and AI-powered content delivery and targeting.
Impiricus was founded by a board-certified dermatologist and a healthcare executive, out of what the company describes as frustration with how healthcare professionals connect with pharmaceutical firms. The mission is directed at serving physicians and their patients, with particular emphasis on reaching underserved providers; the company presents patient access to therapy as its primary impact measure rather than growth rankings alone.
